BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or...
Cancer
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent...
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose...
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed...
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on...
Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the...
Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs...
Mevion and RaySearch: A Synergy of Innovation Transforming Proton Therapy
Mevion and RaySearch re-imagine novel solutions to advance the use of emerging proton therapy technologies and empower medical providers to...
Edward Owusu Kwarteng, Ph.D., BSc, MSc, Honored With The 2023 ASH-CIBMTR-ASTCT Career Development Award
NMDP/Be The Match and the CIBMTR, leaders in Cell Therapy research, provide the award to support future leaders and accelerate...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early...
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Interim results for the six months ended 30 June 2023
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023...
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
Combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early...
Hologic to Expand Outreach During Breast Cancer Awareness Month
Launches Global Partnership With Know Your Lemons, Will Ring Nasdaq Opening Bell for 17th TimeMARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #bcam--Hologic, Inc. (Nasdaq:...
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical...
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted...
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...